Asterias Biotherapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $4.0M | $7.0M | $3.6M | $1.2M | $0 | $0 |
| Operating income | −$6.3M | −$11.2M | −$21.9M | −$17.5M | −$25.7M | −$758,563 |
| Net income | −$28.4M | −$35.5M | −$15.0M | −$10.1M | −$22.4M | −$758,893 |
| Total assets | $43.1M | $61.0M | $57.2M | $44.1M | $80.4M | $4,011 |
| Total liabilities | $9.5M | $19.0M | $12.1M | $11.5M | $26.6M | $761,164 |
| Equity | $33.5M | $42.0M | $45.1M | $32.6M | $53.8M | −$757,000 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | — | — | — | 30.9M | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −155.5%
- Net margin
- −701.9%
- Return on equity
- −84.6%
- Return on assets
- −65.8%
- Return on capital (ROCE)
- −15.9%
- Liabilities / assets
- 22.2%
- Debt / equity
- 0.28×
- Book value / share
- —
- Revenue growth (YoY)
- −41.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -2.85distress
- Accruals / assets
- −9.1%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteMar 8, 2019
- Other material eventMar 1, 2019
- Entered a material agreement · Director / officer change · Other material eventNov 8, 2018
- Entered a material agreement · Terminated a material agreement · New financial obligation · Other material eventOct 1, 2018
- Director / officer changeSep 18, 2018
- Shareholder voteJun 25, 2018
- Director / officer changeDec 5, 2017
- Entered a material agreement · Regulation FD disclosureOct 16, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.